| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IFIT2 |
| Uniprot No | P09913 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-484aa |
| 氨基酸序列 | MSENNKNSLESSLRQLKCHFTWNLMEGENSLDDFEDKVFYRTEFQNREFKATMCNLLAYLKHLKGQNEAALECLRKAEELIQQEHADQAEIRSLVTWGNYAWVYYHMGRLSDVQIYVDKVRHVCEKFSSPYRIESPELDCEEGWTRLKCGGNQNERAKVCFEKALEKKPKNPEFTSGLAIASYRLDNWPPSQNAIDPLRQAIRLNPDNQYLKVLLALKLHKMREEGEEEGEGEKLVEEALEKAPGVTDVLRSAAKFYRRKDEPDKAIELLKKALEYIPNNAYLHCQIGCCYRAKVFQVMNLRENGMYGKRKLLELIGHAVAHLKKADEANDNLFRVCSILASLHALADQYEEAEYYFQKEFSKELTPVAKQLLHLRYGNFQLYQMKCEDKAIHHFIEGVKINQKSREKEKMKDKLQKIAKMRLSKNGADSEALHVLAFLQELNEKMQQADEDSERGLESGSLIPSASSWNGEWRIEMWCPLGYC |
| 分子量 | 82.6 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人IFIT2蛋白的3篇参考文献概览(注：以下内容基于模拟文献，实际引用时请核实原文准确性)：
---
1. **文献名称**：*Structural insight into human IFIT2 protein and its antiviral mechanism*
**作者**：Chen Y, et al.
**摘要**：研究解析了重组人IFIT2蛋白的晶体结构，揭示其通过结合病毒RNA抑制流感病毒复制的分子机制，为靶向IFIT2的抗病毒策略提供结构基础。
2. **文献名称**：*IFIT2 inhibits Ebola virus replication by sequestering viral RNA*
**作者**：Smith JL, et al.
**摘要**：通过体外实验证实重组人IFIT2蛋白能够特异性识别并隔离埃博拉病毒RNA，阻断病毒蛋白翻译，凸显其在先天免疫中的直接抗病毒功能。
3. **文献名称**：*Functional synergy between IFIT2 and IFN-γ in suppressing HIV-1 infection*
**作者**：Zhang R, et al.
**摘要**：研究表明重组IFIT2蛋白与干扰素-γ协同作用，通过上调免疫通路相关基因增强巨噬细胞对HIV-1的清除能力，提示其潜在的免疫调节作用。
---
以上内容综合了结构解析、抗病毒机制及协同免疫研究角度，供初步参考。建议通过学术数据库(如PubMed)以“recombinant human IFIT2”为关键词获取真实文献。
Interferon-induced protein with tetratricopeptide repeats 2 (IFIT2) is a key member of the IFIT family, which plays crucial roles in innate immunity against viral infections. It is encoded by an interferon-stimulated gene (ISG) and rapidly upregulated in response to type I and III interferons (IFNs) during pathogen invasion. IFIT2 contains multiple tetratricopeptide repeat (TPR) motifs, enabling protein-protein interactions critical for its antiviral function. Studies suggest it inhibits viral replication by sequestering viral RNA, disrupting ribosome assembly, or interfering with viral protein translation.
Recombinant human IFIT2 protein, produced via expression systems like *E. coli* or mammalian cells, retains biological activity for functional studies. Its production facilitates research into antiviral mechanisms, host-pathogen interactions, and immune signaling pathways. IFIT2 is implicated in defenses against RNA viruses such as influenza, hepatitis C, and coronaviruses, with emerging roles in cancer and autoimmune regulation. Recombinant IFIT2 is utilized to study structural properties, develop therapeutic agents, and explore diagnostic applications. It also serves as a tool to investigate cooperative antiviral effects with other IFIT proteins (e.g., IFIT1/IFIT3). Current research focuses on harnessing its therapeutic potential, including antiviral drug development and immune-modulating strategies.
×
